Philipp Mathieu - Immunovia Publ CEO Pres

IMMNOV Stock

SEK 0.47 0.02 4.08%

Insider

Philipp Mathieu is CEO Pres of Immunovia publ AB

Phone	46 4 62 75 60 00
Web	https://www.immunovia.com

Immunovia Publ Management Efficiency

The company has return on total asset (ROA) of (0.2617) % which means that it has lost $0.2617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3789) %, meaning that it generated substantial loss on money invested by shareholders. Immunovia Publ's management efficiency ratios could be used to measure how well Immunovia Publ manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Immunovia Publ to Peers

Predict price of Immunovia Publ

Immunovia publ AB has accumulated 27.16 M in total debt with debt to equity ratio (D/E) of 7.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Immunovia publ AB has a current ratio of 13.97, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Immunovia Publ until it has trouble settling it off, either with new capital or with free cash flow. So, Immunovia Publ's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunovia publ AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunovia to invest in growth at high rates of return. When we think about Immunovia Publ's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Christina Herder	Idogen AB	62
	Mikael Svensson	iZafe Group AB	57
	Ann Gidner	Ziccum AB	57
	Prof MBA	Sprint Bioscience AB	64
	Fabrice Rose	Ziccum AB	N/A
	Mr MSc	Idogen AB	61
	Barbro Sjonell	iZafe Group AB	N/A
	Ida Almgren	iZafe Group AB	32
	Rory Graham	Idogen AB	N/A
	Frida Hjelmberg	Ziccum AB	39
	Hanjing Xie	Idogen AB	53
	Prof MD	Idogen AB	82
	Ingvar Karlsson	Idogen AB	67
	Mathias Skalmstad	Sprint Bioscience AB	N/A
	Anders Segerstrom	iZafe Group AB	38

Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people. Immunovia publ AB (IMMNOV) is traded on Stockholm Exchange in Sweden and employs 64 people.

Management Performance

	Return On Equity	-0.38
	Return On Asset	-0.26

Immunovia publ AB Leadership Team

Elected by the shareholders, the Immunovia Publ's board of directors comprises two types of representatives: Immunovia Publ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunovia. The board's role is to monitor Immunovia Publ's management team and ensure that shareholders' interests are well served. Immunovia Publ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunovia Publ's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Linda Mellby, Laboratory Director
	Jeff Borcherding, Immunovia, US
	Philipp Mathieu, CEO Pres
	Karin Liwendahl, Chief Officer

Immunovia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunovia Publ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.38
	Return On Asset	-0.26
	Operating Margin	(201.30) %
	Current Valuation	536.89 M
	Shares Outstanding	22.63 M
	Shares Owned By Insiders	36.15 %
	Shares Owned By Institutions	4.60 %
	Price To Earning	(57.93) X
	Price To Book	2.21 X
	Price To Sales	683.47 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Other Information on Investing in Immunovia Stock

Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC